强烈炎症性肠病中使用生物药和乌帕达西尼布的先进组合疗法:台湾的一项回顾性研究
Ming-Jung Meng1, Chia-Jung Kuo1,2,3,4,5, Ming-Wei Lai2,3,4,5,6
1Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Journal of inflammation research
|March 3, 2025
概括
使用生物药物和Upadacitinib (UPA) 的先进组合疗法 (ACT) 在亚洲对耐药性炎症性肠病 (IBD) 显示出希望. 这项研究发现,基于UPA的ACT在台湾患者中是有效和安全的,反应和缓解率高.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐药性炎症性肠病 (IBD) 带来了重大治疗挑战.
- 生物学家提供治疗选择,但先进的组合疗法 (ACT) 与口服Janus激酶抑制剂如Upadacitinib (UPA) 正在出现.
- 在亚洲人群中,基于UPA的ACT的疗效和安全性仍未得到充分研究.
研究的目的:
- 评估基于UPA的ACT在台湾耐火性IBD患者中的有效性和安全性.
- 提供关于亚洲队列中基于UPA的ACT使用的初步数据.
- 评估与此疗法相关的临床反应,缓解率和不良事件.
主要方法:
- 一项对16名耐火性IBD患者的回顾性研究,这些患者在台湾的一个中心接受了生物药物和UPA治疗.
- 患者从2020年7月至2024年8月进行了随访.
- 临床评估响应和缓解在4,12和24周进行,并对不良事件进行安全监测.
主要成果:
- 观察到高临床响应率:第4周88%,第12周83%,第24周100% .
- 缓解率稳步增加,到第24周达到80%.
- 治疗一般耐受良好,仅报告了一次轻微的不良事件 ();没有出现重大并发症.
结论:
- 本研究提供了来自亚洲的第一个证据,表明基于UPA的ACT是耐火性IBD的有效和安全治疗方法.
- 这些发现表明,基于UPA的ACT可以显著改善该患者群体的临床结果.
- 需要进一步的大规模,多中心的前性研究来验证这些结果,并探索长期疗效和反应预测因素.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
721
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
721
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
703
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
703
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K


